American Heart Journal
Volume 159, Issue 2 , Pages 245-257 , February 2010

Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed

  • Alejandro Macchia, MD

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • Corresponding Author InformationReprint requests: Alejandro Macchia, MD, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8, 66030 Santa Maria Imbaro, Chieti, Italy.
    • ,
  • Roberto Marchioli, MD

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Gianni Tognoni, MD

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Marco Scarano, MS

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • RosaMaria Marfisi, MS

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Luigi Tavazzi, MD

      Affiliations

    • GVM Hospitals of Care and Research, Cotignola, RA, Italy
    • ,
  • Stuart Rich, MD

      Affiliations

    • Section of Cardiology, University of Chicago, Chicago, IL

Received 7 October 2009 ,Accepted 19 November 2009.

References 

  1. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest. 2006;130:1198–1202
  2. Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation. 2008;117:2966–2968
  3. Rich S. The value of approved therapies for pulmonary arterial hypertension. Am Heart J. 2007;153:889–890
  4. Macchia A, Marchioli R, Marfisi RM, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007;153:1037–1047
  5. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med. 1990;112:485–491
  6. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301
  7. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 2000;132:425–434
  8. Olschewski H, Simonneau G, Galiè N, et al. Aerosolized iloprost randomized study group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–329
  9. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–1502
  10. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–804
  11. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–2125
  12. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–1123
  13. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903
  14. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441–447
  15. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur J Respir. 2004;24:353–359
  16. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136:515–522
  17. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet. 2002;360:895–900
  18. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149–1153
  19. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157
  20. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med. 2005;171:1292–1297
  21. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation. 2008;117:3010–3019
  22. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049–2056
  23. Galie N, Beghetti M, Gatzoulis MA, et al. Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Circulation. 2006;114:48–54
  24. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–2100
  25. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521–530
  26. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1–851.e5
  27. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894–2903
  28. McLaughlin VV, Oudiz RJ, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257–1263
  29. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28:691–694
  30. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111
  31. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76
  32. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S–62S
  33. Badesch DB, Abman SH, Simonneau G, et al. Therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917–1928
  34. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial. The role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008;118:1294–1303
  35. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. London, UK: Oxford University Press; 1994;
  36. Agresti A. Categorical data analysis. NewYork: John Wiley and Sons, Inc.; 1990;
  37. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30
  38. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  39. Tabachnick B, Fidell L. Using multivariate statistics. New York (NY): Harper Collins; 1996;
  40. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101
  41. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629
  42. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114:1482–1489
  43. Salzman SH. The 6-min walk test. Clinical and research role, technique, coding, and reimbursement. Chest. 2009;135:1345–1352
  44. Galiè N, Torbicki A, Barst R, et al. Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243–2278
  45. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394–403
  46. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831–841
  47. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004;43:48S–55S
  48. Skali H, Pfeffer MA, Lubsen J, et al. Variable impact of combining fatal and nonfatal endpoints in heart failure trials. Circulation. 2006;114:2298–2303
  49. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343–349
  50. Newman JH. Pulmonary hypertension. Am J Respir Crit Care Med. 2005;172:1072–1077
  51. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation. 2008;118:1195–1201

PII: S0002-8703(09)00953-3

doi: 10.1016/j.ahj.2009.11.028

American Heart Journal
Volume 159, Issue 2 , Pages 245-257 , February 2010

Article Tools

* Image Usage & Resolution